Table 5.
Model 1 | Model 2 | Model 3 | Model 4 | ||
---|---|---|---|---|---|
AKI |
|
OR (95% CI) p value |
|||
Non-Dex | Dex | ||||
eGFR > 90 (mL/min), n = 4908 |
1 | 0.50 (0.33, 0.75) <0.001 | 0.49 (0.32, 0.74) <0.001 | 0.49 (0.33, 0.75) <0.001 | 0.51 (0.37, 0.79) 0.003 |
Blood loss < 1000 mL, n = 6384 |
1 | 0.62 (0.45, 0.86) 0.004 | 0.69 (0.50, 0.96) 0.029 | 0.70 (0.50, 0.98) 0.038 | 0.70 (0.50, 0.98) 0.039 |
NSAIDs = 0, n = 5335 |
1 | 0.57 (0.41, 0.78) <0.001 | 0.65 (0.47, 0.90) <0.001 | 0.67 (0.49, 0.93) 0.018 | 0.67 (0.48, 0.95) 0.027 |
The association between postoperative AKI and Dexmedetomidine in different subgroups. Dex, Dexmedetomidine.
AKI stages (outcome of postoperative AKI was divided into four groups: stage 0, no AKI; stage 1, AKI grade 1; stage 2, AKI grade 2 and stage 3, AKI grade 3).
Model 1: non-adjusted.
Model 2: adjusted for age, sex, eGFR.
Model 3: model 2 plus hypertension, diabetes, diuretics.
Model 4: model 3 plus blood lossed, vasoactive drugs, Hb, Alb, amount of fluid infusion and out, operative time, ASA, lowest MAP and NSAIDs.